ALK1 as an emerging target for antiangiogenic therapy of cancer

Blood

Volumn 117, Issue 26, 2011, Pages 6999-7006

  Cunha, Sara I ^a   Pietras, Kristian ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACE 041; ACTIVIN RECEPTOR LIKE KINASE 1; ANTINEOPLASTIC AGENT; BONE MORPHOGENETIC PROTEIN 9; ENDOGLIN; FIBROBLAST GROWTH FACTOR; INHIBITOR OF DIFFERENTIATION 1; INHIBITOR OF DIFFERENTIATION 3; PF 3446962; RAP 041; SMAD1 PROTEIN; SMAD4 PROTEIN; SMAD5 PROTEIN; SMAD8 PROTEIN; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 3;

ADVANCED CANCER; ANGIOGENESIS; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTERIOVENOUS MALFORMATION; BLEEDING; BREAST CARCINOMA; CANCER GROWTH; CANCER SURVIVAL; CARCINOGENESIS; CELL ADHESION; CELL DIFFERENTIATION; CELL FATE; CELL MIGRATION; CELL PROLIFERATION; EMBRYO DEVELOPMENT; ENDOTHELIUM CELL; FATIGUE; GENE TARGETING; HOMEOSTASIS; HUMAN; HYPERTENSION; LIGAND BINDING; LOSS OF FUNCTION MUTATION; LUNG CIRCULATION; LYMPHANGIOGENESIS; MAXIMUM TOLERATED DOSE; MELANOMA; MESENCHYMAL STEM CELL; NAUSEA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PULMONARY HYPERTENSION; RENDU OSLER WEBER DISEASE; REVIEW; SOLID TUMOR; TISSUE SPECIFICITY; UPREGULATION; VASCULARIZATION;

EID: 79959850956     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-01-330142     Document Type: Review

References (86)

1. ten Dijke P, Ichijo H, Franzén P, et al. Activin receptor-like kinases: a novel subclass of cell-surface receptors with predicted serine/threonine kinase activity. Oncogene. 1993;8:2879-2887.
2. Massagué J. How cells read TGF-beta signals. Nat Rev Mol Cell Biol. 2000;1(3):169-178.
3. Schmierer B, Hill CS. TGFbeta-smad signal transduction: molecular specificity and functional flexibility. Nat Rev Mol Cell Biol. 2007;8(12):970-982. (Pubitemid 350174642)
4. Wrana JL, Attisano L, Wieser R, Ventura F, Massagué J. Mechanism of activation of the TGF-beta receptor. Nature. 1994;370(6488):341-347. (Pubitemid 2110860)
5. ten Dijke P, Miyazono K, Heldin C-H. Signaling inputs converge on nuclear effectors in TGF-beta signaling. Trends Biol Sci. 2000;25(2):64-70.
6. Macías-Silva M, Hoodless PA, Tang SJ, Buchwald M, Wrana JL. Specific activation of smad1 signaling pathways by the bmp7 type i receptor, alk2. J Biol Chem. 1998;273(40):25628-25636. (Pubitemid 28475783)
7. Chen YG, Massagué J. Smad1 recognition and activation by the alk1 group of transforming growth factor-beta family receptors. J Biol Chem. 1999;274(6):3672-3677. (Pubitemid 29077212)
8. Macías-Silva M, Abdollah S, Hoodless PA, Pirone R, Attisano L, Wrana JL. Madr2 is a substrate of the TGFbeta receptor and its phosphorylation is required for nuclear accumulation and signaling. Cell. 1996;87(7):1215-1224. (Pubitemid 27010105)
9. Nakao A, Imamura T, Souchelnytskyi S, et al. TGF-beta receptor-mediated signalling through smad2, smad3 and smad4. EMBO J. 1997;16(17):5353-5362. (Pubitemid 27380143)
10. Derynck R, Zhang Y, Feng X-H. Smads: Transcriptional activators of TGF-beta responses. Cell. 1998;95(6):737-740. (Pubitemid 29014453)
11. Itoh S, Itoh F, Goumans MJ, ten Dijke P. Signaling of transforming growth factor-beta family members through smad proteins. Eur J Biochem. 2000;267(24):6954-6967. (Pubitemid 32009435)
12. Moustakas A, Heldin CH. Non-smad TGF-beta signals. J Cell Sci. 2005;118(pt 16):3573-3584.
13. Jonker L, Arthur HM. Endoglin expression in early development is associated with vasculogenesis and angiogenesis. Mech Dev. 110(1-2):193-196, 2002.
14. Torsney E, Charlton R, Parums D, Collis M, Arthur HM. Inducible expression of human endoglin during inflammation and wound healing in vivo. Inflamm Res. 2002;51(9):464-470.
15. ten Dijke P, Goumans MJ, Pardali E. Endoglin in angiogenesis and vascular diseases. Angiogenesis. 2008;11(1):79-89.
16. Lebrin F, Goumans MJ, Jonker L, et al. Endoglin promotes endothelial cell proliferation and TGF-beta/alk1 signal transduction. EMBO J. 2004;23(20):4018-4028. (Pubitemid 39472423)
17. Goumans MJ, Valdimarsdottir G, Itoh S, Rosendahl A, Sideras P, ten Dijke P. Balancing the activation state of the endothelium via two distinct TGF-beta type i receptors. EMBO J. 2002;21(7):2580-2590.
18. Oh SP, Seki T, Goss KA, et al. Activin receptor-like kinase 1 modulates transforming growth factor-beta 1 signaling in the regulation of angiogenesis. Proc Natl Acad Sci U S A. 2000;97(6): 2626-2631. (Pubitemid 30159221)
19. Valdimarsdottir G, Goumans MJ, Rosendahl A, et al. Stimulation of id1 expression by bone morphogenetic protein is sufficient and necessary for bone morphogenetic protein-induced activation of endothelial cells. Circulation. 2002;106(17):2263-2270. (Pubitemid 35222223)
20. Lamouille S, Mallet C, Feige JJ, Bailly S. Activin receptor-like kinase 1 is implicated in the maturation phase of angiogenesis. Blood. 2002;100(13):4495-4501. (Pubitemid 35429690)
21. Finnson KW, Parker WL, ten Dijke P, Thorikay M, Philip A. Alk1 opposes alk5/smad3 signaling and expression of extracellular matrix components in human chondrocytes. J Bone Miner Res. 2008;23(6):896-906. (Pubitemid 351768808)
22. David L, Mallet C, Mazerbourg S, Feige JJ, Bailly S. Identification of bmp9 and bmp10 as functional activators of the orphan activin receptor-like kinase 1 (alk1) in endothelial cells. Blood. 2007;109(5):1953-1961. (Pubitemid 46348192)
23. Scharpfenecker M, van Dinther M, Liu Z, et al. Bmp-9 signals via alk1 and inhibits bfgf-induced endothelial cell proliferation and vegf-stimulated angiogenesis. J Cell Sci. 2007;120(pt 6):964-972. (Pubitemid 46638511)
24. Suzuki Y, Ohga N, Morishita Y, Hida K, Miyazono K, Watabe T. Bmp-9 induces proliferation of multiple types of endothelial cells in vitro and in vivo. J Cell Sci. 2010;123(pt 10):1684-1692.
25. Cunha SI, Pardali E, Thorikay M, et al. Genetic and pharmacological targeting of activin receptorlike kinase 1 impairs tumor growth and angiogenesis. J Exp Med. 2010;207(1):85-100.
26. Upton PD, Davies RJ, Trembath RC, Morrell NW. Bone morphogenetic protein (bmp) and activin type ii receptors balance bmp9 signals mediated by activin receptor-like kinase-1 in human pulmonary artery endothelial cells. J Biol Chem. 2009; 284(23):15794-15804.
27. Blaney Davidson EN, Remst DF, Vitters EL, et al. Increase in alk1/alk5 ratio as a cause for elevated mmp-13 expression in osteoarthritis in humans and mice. J Immunol. 2009;182(12):7937-7945.
28. Ota T, Fujii M, Sugizaki T, et al. Targets of transcriptional regulation by two distinct type i receptors for transforming growth factor-beta in human umbilical vein endothelial cells. J Cell Physiol. 2002;193(3):299-318. (Pubitemid 35265950)
29. Seki T, Hong KH, Oh SP. Nonoverlapping expression patterns of alk1 and alk5 reveal distinct roles of each receptor in vascular development. Lab Invest. 2006;86(2):116-129. (Pubitemid 43117592)
30. Goumans MJ, Valdimarsdottir G, Itoh S, et al. Activin receptor-like kinase (alk)1 is an antagonistic mediator of lateral TGFbeta /alk5 signaling. Mol Cell. 2003;12(4):817-828. (Pubitemid 37352776)
31. Shao ES, Lin L, Yao Y, Bostrom KI. Expression of vascular endothelial growth factor is coordinately regulated by the activin-like kinase receptors 1 and 5 in endothelial cells. Blood. 2009;114(10):2197-2206.
32. Park SO, Lee YJ, Seki T, et al. Alk5- and TGFbr2-independent role of alk1 in the pathogenesis of hereditary hemorrhagic telangiectasia type 2. Blood. 2008;111(2):633-642.
33. Itoh F, Itoh S, Carvalho RL, et al. Poor vessel formation in embryos from knock-in mice expressing alk5 with l45 loop mutation defective in smad activation. Lab Invest. 2009;89(7):800-810.
34. Chen H, Shi S, Acosta L, et al. Bmp10 is essential for maintaining cardiac growth during murine cardiogenesis. Development. 2004;131(9):2219-2231. (Pubitemid 38702052)
35. Yao Y, Shao ES, Jumabay M, Shahbazian A, Ji S, Bostrom KI. High-density lipoproteins affect endothelial bmp-signaling by modulating expression of the activin-like kinase receptor 1 and 2. Arterioscler Thromb Vasc Biol. 2008;28(12):2266-2274.
36. Boström KI, Jumabay M, Matveyenko A, Nicholas SB, Yao Y. Activation of vascular bone morphogenetic protein signaling in diabetes mellitus. Circ Res. 2011;108(4):446-457.
37. Medici D, Shore EM, Lounev VY, Kaplan FS, Kalluri R, Olsen BR. Conversion of vascular endothelial cells into multipotent stem-like cells. Nat Med. 2010;16(12):1400-1406.
38. Zeisberg EM, Potenta S, Xie L, Zeisberg M, Kalluri R. Discovery of endothelial to mesenchymal transition as a source for carcinomaassociated fibroblasts. Cancer Res. 2007;67(21):10123-10128. (Pubitemid 350070783)
39. Ramoshebi LN, Ripamonti U. Osteogenic protein-1, a bone morphogenetic protein, induces angiogenesis in the chick chorioallantoic membrane and synergizes with basic fibroblast growth factor and transforming growth factor-beta 1. Anat Rec. 2000;259(1):97-107. (Pubitemid 30244075)
40. Langenfeld EM, Langenfeld J. Bone morphogenetic protein-2 stimulates angiogenesis in developing tumors. Mol Cancer Res. 2004;2(3):141-149. (Pubitemid 39030304)
41. Heinke J, Wehofsits L, Zhou Q, et al. Bmper is an endothelial cell regulator and controls bone morphogenetic protein-4-dependent angiogenesis. Circ Res. 2008;103(8):804-812.
42. Herrera B, van Dinther M, Ten Dijke P, Inman GJ. Autocrine bone morphogenetic protein-9 signals through activin receptor-like kinase-2/smad1/ smad4 to promote ovarian cancer cell proliferation. Cancer Res. 2009;69(24):9254-9262.
43. Luo J, Tang M, Huang J, et al. TGFbeta/bmp type i receptors alk1 and alk2 are essential for bmp9-induced osteogenic signaling in mesenchymal stem cells. J Biol Chem. 2010;285(38):29588-29598.
44. Wang J, Sridurongrit S, Dudas M, et al. Atrioventricular cushion transformation is mediated by alk2 in the developing mouse heart. Dev Biol. 2005;286(1):299-310. (Pubitemid 41394064)
45. Kitao A, Sato Y, Sawada-Kitamura S, et al. Endothelial to mesenchymal transition via transforming growth factor-beta1/smad activation is associated with portal venous stenosis in idiopathic portal hypertension. Am J Pathol. 2009;175(2):616-626.
46. Nohe A, Hassel S, Ehrlich M, et al. The mode of bone morphogenetic protein (bmp) receptor oligomerization determines different bmp-2 signaling pathways. J Biol Chem. 2002;277(7):5330-5338. (Pubitemid 34968578)
47. Nohe A, Keating E, Knaus P, Petersen NO. Signal transduction of bone morphogenetic protein receptors. Cell Signal. 2004;16(3):291-299. (Pubitemid 37542404)
48. Foletta VC, Lim MA, Soosairajah J, et al. Direct signaling by the bmp type ii receptor via the cyto-skeletal regulator limk1. J Cell Biol. 2003;162(6):1089-1098. (Pubitemid 37174191)
49. Lee-Hoeflich ST, Causing CG, Podkowa M, Zhao X, Wrana JL, Attisano L. Activation of limk1 by binding to the bmp receptor, bmprii, regulates bmp-dependent dendritogenesis. EMBO J. 2004; 23(24):4792-4801. (Pubitemid 40069709)
50. Bernabeu C, Conley BA, Vary CP. Novel bio-chemical pathways of endoglin in vascular cell physiology. J Cell Biochem. 2007;102(6):1375-1388. (Pubitemid 350223941)
51. Pece-Barbara N, Vera S, Kathirkamathamby K, et al. Endoglin null endothelial cells proliferate faster and are more responsive to transforming growth factor beta1 with higher affinity receptors and an activated alk1 pathway. J Biol Chem. 2005;280(30):27800-27808. (Pubitemid 41076895)
52. Cheifetz S, Bellon T, Cales C, et al. Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. J Biol Chem. 1992;267(27):19027-19030.
53. Barbara NP, Wrana JL, Letarte M. Endoglin is an accessory protein that ineracts with the signaling receptor complex of multiple members of the transforming growth factor-beta superfamily. J Biol Chem. 1999;274(2):584-594.
54. Roelen BA, van Rooijen MA, Mummery CL. Expression of alk-1, a type 1 serine/threonine kinase receptor, coincides with sites of vasculo-genesis and angiogenesis in early mouse development. Dev Dyn. 1997;209(4):418-430. (Pubitemid 27328468)
55. Wiercinska E, Wickert L, Denecke B, et al. Id1 is a critical mediator in TGF-beta-induced transdifferentiation of rat hepatic stellate cells. Hepatology. 2006;43(5):1032-1041. (Pubitemid 43738969)
56. Wu X, Robinson CE, Fong HW, et al. Cloning and characterization of the murine activin receptor like kinase-1 (alk-1) homolog. Biochem Biophys Res Commun. 1995;216(1):78-83.
57. Panchenko MP, Williams MC, Brody JS, Yu Q. Type i receptor serine threonine kinase preferentially expressed in pulmonary blood vessels. Am J Physiol Lung Cell Mol Physiol. 1996;270(4):L547-L558.
58. Bertolino P, Deckers M, Lebrin F, ten Dijke P. Transforming growth factor-beta signal transduction in angiogenesis and vascular disorders. Chest. 2005;128(6 suppl):585S-590S.
59. Roman BL, Pham VN, Lawson ND, et al. Disruption of acvrl1 increases endothelial cell number in zebrafish cranial vessels. Development. 2002; 129(12):3009-3019. (Pubitemid 34874278)
60. Hong KH, Seki T, Oh SP. Activin receptor-like kinase 1 is essential for placental vascular development in mice. Lab Invest. 2007;87(7):670-679. (Pubitemid 46920104)
61. ten Dijke P, Arthur HM. Extracellular control of TGFbeta signalling in vascular development and disease. Nat Rev Mol Cell Biol. 2007;8(11):857-869.
62. McAllister KA, Grogg KM, Johnson DW, et al. Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nature Genet. 1994;8(4):345-351.
63. Johnson DW, Berg JN, Baldwin MA, et al. Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat Genet. 1996;13:189-195.
64. Arthur HM, Ure J, Smith AJ, et al. Endoglin, an ancillary TGFbeta receptor, is required for extra-embryonic angiogenesis and plays a key role in heart development. Dev Biol. 2000;217(1):42-53. (Pubitemid 30046798)
65. Srinivasan S, Hanes MA, Dickens T, et al. A mouse model for hereditary hemorrhagic telangiectasia (hht) type 2. Hum Mol Genet. 2003;12(5):473-482. (Pubitemid 36305588)
66. Torsney E, Charlton R, Diamond AG, Burn J, Soames JV, Arthur HM. Mouse model for hereditary hemorrhagic telangiectasia has a generalized vascular abnormality. Circulation. 2003;107(12):1653-1657. (Pubitemid 36397335)
67. Park SO, Wankhede M, Lee YJ, et al. Real-time imaging of de novo arteriovenous malformation in a mouse model of hereditary hemorrhagic telangiectasia. J Clin Invest. 2009;119(11):3487-3496.
68. Lyden D, Young AZ, Zagzag D, et al. Id1 and id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts. Nature. 1999;401(6754):670-677.
69. Gao D, Nolan DJ, Mellick AS, Bambino K, McDonnell K, Mittal V. Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis. Science. 2008;319(5860):195-198.
70. Niessen K, Zhang G, Ridgway JB, Chen H, Yan M. Alk1 signaling regulates early postnatal lymphatic vessel development. Blood. 2010;115(8):1654-1661.
71. Mitchell D, Pobre EG, Mulivor AW, et al. Alk1-fc inhibits multiple mediators of angiogenesis and suppresses tumor growth. Mol Cancer Ther. 2010;9(2):379-388.
72. Yu PB, Hong CC, Sachidanandan C, et al. Dorsomorphin inhibits bmp signals required for embryo-genesis and iron metabolism. Nat Chem Biol. 2008;4(1):33-41. (Pubitemid 350273653)
73. Boergermann JH, Kopf J, Yu PB, Knaus P. Dorsomorphin and ldn-193189 inhibit bmp-mediated smad, p38 and akt signalling in c2c12 cells. Int J Biochem Cell Biol. 2010;42(11):1802-1807.
74. Yu PB, Deng DY, Lai CS, et al. Bmp type i receptor inhibition reduces heterotopic [corrected] ossification. Nat Med. 2008;14(12):1363-1369.
75. Hao J, Ho JN, Lewis JA, et al. In vivo structure-activity relationship study of dorsomorphin analogues identifies selective vegf and bmp inhibitors. ACS Chem Biol. 2010;5(2):245-253.
76. Goff LW, De Braud FG, Cohen RB, et al. Phase i study of pf-03446962, a fully human mab against alk 1, a TGFbeta receptor involved in tumor angiogenesis. J Clin Oncol (Meeting Abstracts). 2010;28(15 suppl):3034.
77. Borgstein NG, Sharma S, Bendell JC, et al. Phase i study of ace-041, a novel inhibitor of vascular maturation, in patients with advanced solid tumors or relapsed/refractory multiple myeloma. J Clin Oncol (Meeting Abstracts). 2010;28(15 suppl):TPS179.
78. Hu-Lowe DD, Chen E, Zhang L, et al. Targeting activin receptor-like kinase 1 (alk1) inhibits angio-genesis and tumorigenesis through a mechanism of action complementary to anti-vegf therapies. Cancer Res. 2011;71(4):1362-1373.
79. Erbersdobler A, Simon R, Hellwinkel OJ, et al. Analysis of expression of TGF-beta1 receptor (alk-1) in normal and tumor tissues by tissue microarrays. J Clin Oncol (Meeting Abstracts). 2009;27(15S):e22044.
80. Pontén F, Jirström K, Uhlen M. The human protein atlas - a tool for pathology. J Pathol. 2008; 216(4):387-393.
81. Wikström P, Stattin P, Franck-Lissbrant I, Damber JE, Bergh A. Transforming growth factor beta1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer. Prostate. 1998;37(1):19-29. (Pubitemid 28385181)
82. Machado RD, Eickelberg O, Elliott CG, et al. Genetics and genomics of pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54 (1 suppl):S32-42.
83. Ungefroren H, Schniewind B, Groth S, et al. Anti-tumor activity of alk1 in pancreatic carcinoma cells. Int J Cancer. 2007;120(8):1641-1651. (Pubitemid 46399348)
84. Alexander JM, Bikkal HA, Zervas NT, Laws ER, Jr., Klibanski A. Tumor-specific expression and alternate splicing of messenger ribonucleic acid encoding activin transforming growth factor-beta receptors in human pituitary adenomas. J Clin Endocrinol Metab. 1996;81(2):783-790. (Pubitemid 26055700)
85. Mancuso P, Shalinsky DR, Calleri A, et al. Evaluation of alk-1 expression in circulating endothelial cells (cecs) as an exploratory biomarker for pf-03446962 undergoing phase i trial in cancer patients. J Clin Oncol (Meeting Abstracts). 2009;27(15S):3573.
86. Ikushima H, Miyazono K. TGFbeta signalling: A complex web in cancer progression. Nat Rev Cancer. 2010;10(6):415-424.